Lumateperone

Atypical antipsychotic medication

Lumateperone
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Lumateperone, marketed under the brand name Caplyta, is an atypical antipsychotic medication used primarily in the treatment of schizophrenia and bipolar disorder. It was developed by Intra-Cellular Therapies and received approval from the United States Food and Drug Administration (FDA) in December 2019.

Pharmacology

Lumateperone acts as a serotonin receptor antagonist, dopamine receptor partial agonist, and serotonin transporter inhibitor. Its mechanism of action is thought to involve modulation of the serotonin (5-HT2A) and dopamine (D2) receptors, which are implicated in the pathophysiology of schizophrenia and bipolar disorder. This unique receptor activity profile is believed to contribute to its efficacy and tolerability.

Mechanism of Action

Lumateperone's antipsychotic effects are primarily attributed to its antagonism of the 5-HT2A receptor and partial agonism at the D2 receptor. Additionally, it has moderate affinity for the serotonin transporter, which may enhance its therapeutic effects. Unlike many other antipsychotics, lumateperone has minimal activity at the histamine and muscarinic acetylcholine receptors, which may reduce the risk of side effects such as sedation and anticholinergic effects.

Clinical Use

Lumateperone is indicated for the treatment of schizophrenia in adults. It is also approved for the treatment of depressive episodes associated with bipolar I or II disorder, either as monotherapy or as adjunctive therapy with lithium or valproate.

Dosage and Administration

Lumateperone is administered orally, typically at a dose of 42 mg once daily with food. The dosage may be adjusted based on clinical response and tolerability.

Side Effects

Common side effects of lumateperone include somnolence, dry mouth, and dizziness. It has a lower risk of causing extrapyramidal symptoms compared to other antipsychotics. Weight gain and metabolic disturbances are also less common with lumateperone.

History

Lumateperone was developed by Intra-Cellular Therapies, a biopharmaceutical company focused on the development of novel drugs for the treatment of neuropsychiatric and neurological disorders. The drug was approved by the FDA for the treatment of schizophrenia in December 2019 and for bipolar depression in December 2021.

Research

Ongoing research is exploring the potential of lumateperone in other psychiatric conditions, including major depressive disorder and autism spectrum disorder. Studies are also investigating its long-term safety and efficacy.

Related pages

• Schizophrenia
• Bipolar disorder
• Atypical antipsychotic
• Serotonin
• Dopamine